115 related articles for article (PubMed ID: 1879086)
21. Oral iloprost as a treatment for Raynaud's syndrome: a double blind multicentre placebo controlled study.
Belch JJ; Capell HA; Cooke ED; Kirby JD; Lau CS; Madhok R; Murphy E; Steinberg M
Ann Rheum Dis; 1995 Mar; 54(3):197-200. PubMed ID: 7538285
[TBL] [Abstract][Full Text] [Related]
22. Increased prostacyclin metabolites and decreased red cell deformability in patients with systemic sclerosis and Raynauds syndrome.
Belch JJ; McLaren M; Anderson J; Lowe GD; Sturrock RD; Capell HA; Forbes CD
Prostaglandins Leukot Med; 1985 Jan; 17(1):1-9. PubMed ID: 3883365
[TBL] [Abstract][Full Text] [Related]
23. Effect of prostacyclin on platelets, polymorphonuclear cells, and heterotypic cell aggregation during hemofiltration.
Kozek-Langenecker SA; Spiss CK; Michalek-Sauberer A; Felfernig M; Zimpfer M
Crit Care Med; 2003 Mar; 31(3):864-8. PubMed ID: 12626998
[TBL] [Abstract][Full Text] [Related]
24. Platelet-aggregation inhibition and hemodynamic effects of beraprost sodium, a new oral prostacyclin derivative: a study in healthy male subjects.
Nony P; Ffrench P; Girard P; Delair S; Azoulay S; Girre JP; Dechavanne M; Boissel JP
Can J Physiol Pharmacol; 1996 Aug; 74(8):887-93. PubMed ID: 8960377
[TBL] [Abstract][Full Text] [Related]
25. Successful treatment of patients with severe secondary Raynaud's phenomenon with the endothelin receptor antagonist bosentan.
Selenko-Gebauer N; Duschek N; Minimair G; Stingl G; Karlhofer F
Rheumatology (Oxford); 2006 Oct; 45 Suppl 3():iii45-8. PubMed ID: 16987835
[TBL] [Abstract][Full Text] [Related]
26. In vivo studies with the stabilized epoprostenol analogue taprostene. Effects on platelet functions and blood clotting.
Michel G; Seipp U
Arzneimittelforschung; 1990 Aug; 40(8):932-8. PubMed ID: 2242087
[TBL] [Abstract][Full Text] [Related]
27. Pharmacokinetics of oral iloprost in patients with Raynaud's phenomenon secondary to systemic sclerosis.
Janssena MC; Wollersheim H; Kraus C; Hildebrand M; Watson HR; Thien T
Prostaglandins Other Lipid Mediat; 2000 Mar; 60(4-6):153-60. PubMed ID: 10751645
[TBL] [Abstract][Full Text] [Related]
28. Plasma adrenomedullin and endothelin-1 levels are reduced and Raynaud's phenomenon improved by daily tadalafil administration in male patients with systemic sclerosis.
Rosato E; Letizia C; Proietti M; Aversa A; Menghi G; Rossi C; Torella E; Cotesta D; Petramala L; Bruzziches R; Spera G; Pisarri S; Salsano F
J Biol Regul Homeost Agents; 2009; 23(1):23-9. PubMed ID: 19321043
[TBL] [Abstract][Full Text] [Related]
29. Use of prostacyclin and its analogues in the treatment of cardiovascular disease.
Fink AN; Frishman WH; Azizad M; Agarwal Y
Heart Dis; 1999; 1(1):29-40. PubMed ID: 11720602
[TBL] [Abstract][Full Text] [Related]
30. Prolonged increase in digital blood flow following iloprost infusion in patients with systemic sclerosis.
Rademaker M; Thomas RH; Provost G; Beacham JA; Cooke ED; Kirby JD
Postgrad Med J; 1987 Aug; 63(742):617-20. PubMed ID: 2447572
[TBL] [Abstract][Full Text] [Related]
31. Iloprost treatment in patients with Raynaud's phenomenon secondary to systemic sclerosis and the quality of life: a new therapeutic protocol.
Milio G; Corrado E; Genova C; Amato C; Raimondi F; Almasio PL; Novo S
Rheumatology (Oxford); 2006 Aug; 45(8):999-1004. PubMed ID: 16484290
[TBL] [Abstract][Full Text] [Related]
32. Elastase release following myocardial ischemia during extracorporeal circulation (ECC) -- marker of ongoing systemic inflammation?
Boeken U; Feindt P; Schulte HD; Gams E
Thorac Cardiovasc Surg; 2002 Jun; 50(3):136-40. PubMed ID: 12077684
[TBL] [Abstract][Full Text] [Related]
33. Responses to nifedipine by patients with Raynaud's disease and Raynaud's phenomenon secondary to another disease.
Riccio A; Del Puente A; Farinaro C; Scarpa R; Oriente P; Rocco P; Gioia M
Clin Ther; 1987; 9(2):232-7. PubMed ID: 3568066
[TBL] [Abstract][Full Text] [Related]
34. Increased whole blood platelet aggregation in patients with Raynaud's phenomenon with or without systemic sclerosis.
Lau CS; McLaren M; Saniabadi A; Belch JJ
Scand J Rheumatol; 1993; 22(3):97-101. PubMed ID: 8316776
[TBL] [Abstract][Full Text] [Related]
35. Statins: potentially useful in therapy of systemic sclerosis-related Raynaud's phenomenon and digital ulcers.
Abou-Raya A; Abou-Raya S; Helmii M
J Rheumatol; 2008 Sep; 35(9):1801-8. PubMed ID: 18709692
[TBL] [Abstract][Full Text] [Related]
36. Antithrombotic effects of KP-10614, a novel and stable prostacyclin (PGI2) analog.
Kanayama T; Kimura Y; Iseki K; Hayashi Y; Tamao Y; Mizogami S
J Pharmacol Exp Ther; 1990 Dec; 255(3):1210-7. PubMed ID: 1702154
[TBL] [Abstract][Full Text] [Related]
37. Effect of ketanserin on Raynaud's phenomenon in progressive systemic sclerosis: a double-blind trial.
Lukác J; Rovenský J; Tauchmannová H; Zitnan D
Drugs Exp Clin Res; 1985; 11(9):659-63. PubMed ID: 3916837
[TBL] [Abstract][Full Text] [Related]
38. Inhaled prostacyclin and platelet function after cardiac surgery and cardiopulmonary bypass.
Haraldsson A; Kieler-Jensen N; Wadenvik H; Ricksten SE
Intensive Care Med; 2000 Feb; 26(2):188-94. PubMed ID: 10784307
[TBL] [Abstract][Full Text] [Related]
39. Effects of long-term cyclic iloprost therapy in systemic sclerosis with Raynaud's phenomenon. A randomized, controlled study.
Scorza R; Caronni M; Mascagni B; Berruti V; Bazzi S; Micallef E; Arpaia G; Sardina M; Origgi L; Vanoli M
Clin Exp Rheumatol; 2001; 19(5):503-8. PubMed ID: 11579708
[TBL] [Abstract][Full Text] [Related]
40. Effect of chronic ketanserin treatment on serotonin-induced platelet aggregation in patients with Raynaud's phenomenon.
Marasini B; Biondi ML; Mollica R
Eur J Clin Pharmacol; 1990; 39(3):289-90. PubMed ID: 2257869
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
